Legend Biotech
LEGN
15.25
-0.85
-5.28%
Legend Biotech
US · LEGN
#2374 by market cap
Listed 2020
15.25
-0.85
-5.28%
Periodic snapshot; not a real-time feed.
· 2026-11-20 20:02
✦ Quant Financial Health how this is computed
Weak
- Altman Z-Score is 1.60, below the 1.8 "distress zone" threshold.
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 8 years
Latest year +64.02% YoY
Margins
- Gross margin
- 60.34%
- Operating margin
- -13.27%
- Net margin
- -28.85%
Key ratios & quality
- Altman Z-Scorei
- 1.60
Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 49.13M | 57.26M | 75.00M | 68.83M | 117.01M | 285.10M | 627.30M | 1.03B |
| Gross profit | -- | -- | 75.00M | 68.83M | 51.64M | 140.90M | 392.70M | 620.80M |
| Selling & admin expenses | 3.93M | 32.37M | 72.71M | 149.50M | 174.05M | 201.00M | 284.30M | 341.60M |
| Research & development | 60.64M | 161.94M | 232.16M | 313.35M | 335.65M | 382.20M | 413.50M | 414.70M |
| Operating profit | -15.07M | -135.37M | -226.79M | -392.29M | -455.62M | -528.10M | -309.50M | -136.50M |
| Pretax profit | -1.62M | -130.37M | -308.29M | -407.20M | -445.72M | -520.20M | -158.10M | -282.60M |
| Tax | 1.17M | 2.60M | -41.91M | -3.61M | 625.00K | -1.90M | 18.90M | 14.20M |
| Net profit | -2.78M | -132.97M | -266.37M | -403.58M | -446.35M | -518.30M | -177.00M | -296.80M |
| Basic EPS | 0 | -1 | -2 | -3 | -3 | -3 | -1 | -2 |
| Diluted EPS | -0.03 | -1.33 | -2.26 | -2.86 | -2.80 | -2.94 | -0.96 | -1.62 |
| Line item | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 | 2026-09 |
|---|---|---|---|---|---|---|
| Revenue | 255.10M | 272.40M | 306.40M | 305.10M | 387.50M | 359.50M |
| Gross profit | 157.10M | 157.10M | 182.90M | 129.20M | 250.10M | 211.90M |
| Selling & admin expenses | 80.70M | 87.20M | 101.20M | 90.10M | 96.40M | 69.80M |
| Research & development | 98.30M | 113.20M | 101.30M | 85.70M | 96.00M | 95.30M |
| Operating profit | -21.90M | -43.30M | -19.60M | -49.80M | 57.70M | 46.80M |
| Pretax profit | -124.80M | -39.00M | -19.60M | -53.10M | 55.50M | 49.40M |
| Tax | 600.00K | 600.00K | 11.20M | 1.20M | 22.30M | -2.30M |
| Net profit | -125.40M | -39.60M | -30.80M | -54.30M | 33.20M | 51.70M |
| Basic EPS | -1 | 0 | 0 | 0 | 0 | 0 |
| Diluted EPS | -0.68 | -0.22 | -0.16 | -0.30 | 0.18 | 0.26 |
Balance sheet
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | 326.96M | 207.10M | 593.94M | 949.85M | 1.10B | 1.50B | 1.28B | 1.25B |
| Cash & ST investments | 216.18M | 158.92M | 505.69M | 882.40M | 1.03B | 1.31B | 1.12B | 948.60M |
| Inventory | 1.14M | 1.16M | 1.80M | 1.75M | 10.35M | 19.43M | 23.90M | 32.00M |
| Total assets | 429.05M | 287.72M | 722.09M | 1.12B | 1.33B | 1.85B | 1.67B | 1.73B |
| Total current liabilities | 159.19M | 127.76M | 115.57M | 229.20M | 297.79M | 216.42M | 277.70M | 636.40M |
| Short-term debt | 373.00K | 1.03M | 1.46M | 911.00K | 3.56M | 3.18M | 4.80M | 326.50M |
| Long-term debt | -- | -- | -- | 120.46M | 260.93M | 281.33M | 301.20M | -- |
| Total liabilities | 420,398,000.00 | 410,584,000.00 | 124,322,000.00 | 353,521,000.00 | 586,651,000.00 | 597,238,000.00 | 629,600,000.00 | 731,600,000.00 |
| Total equity | 8.65M | -122.87M | 597.77M | 765.94M | 744.31M | 1.25B | 1.04B | 1.00B |
| Retained earnings | 5.69M | -127.28M | -116.53M | -520.11M | -966.46M | -1.48B | -1.66B | -1.96B |
| Line item | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 | 2026-09 |
|---|---|---|---|---|---|---|
| Total current assets | 1.25B | 1.24B | 1.25B | 1.08B | 1.23B | 1.14B |
| Cash & ST investments | 967.56M | 992.59M | 948.60M | 834.60M | 964.60M | 852.50M |
| Inventory | 35.59M | 29.18M | 32.00M | 37.10M | 41.50M | 39.80M |
| Total assets | 1.69B | 1.71B | 1.73B | 1.60B | 1.75B | 1.68B |
| Total current liabilities | 265.48M | 433.57M | 636.40M | 509.10M | 403.60M | 289.60M |
| Short-term debt | 5.91M | 150.25M | 326.50M | 277.20M | 168.20M | 55.90M |
| Long-term debt | 310.26M | 171.93M | -- | -- | -- | -- |
| Total liabilities | 654,375,000.00 | 701,688,000.00 | 731,600,000.00 | 629,000,000.00 | 521,300,000.00 | 408,700,000.00 |
| Total equity | 1.04B | 1.01B | 1.00B | 967.70M | 1.23B | 1.27B |
| Retained earnings | -1.89B | -1.93B | -1.96B | -2.01B | -1.98B | -1.93B |
Cash flow
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 307.68M | -83.07M | -223.01M | -198.47M | -201.28M | -393.30M | -144.00M | -100.20M |
| Depreciation & amortization | 1.68M | 5.26M | 9.93M | 13.92M | 18.39M | 18.50M | 21.40M | 28.90M |
| Free cash flow | 286.66M | -122.24M | -253.29M | -243.87M | -223.56M | -416.00M | -158.10M | -128.80M |
| Dividends paid | -- | -- | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | 0 | 0 | 462.09M | 623.44M | 377.64M | 583.70M | 0 | 0 |
| Ending cash balance | 210.17M | 83.36M | 455.69M | 688.94M | 786.03M | 1.28B | 286.70M | 901.90M |
| Line item | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 | 2026-09 |
|---|---|---|---|---|---|---|
| Operating cash flow | -13.20M | 28.80M | -12.20M | -85.10M | -20.90M | -35.90M |
| Depreciation & amortization | 5.80M | 6.00M | 12.00M | 15.60M | 11.70M | 11.00M |
| Free cash flow | -22.40M | 23.80M | -24.60M | -92.60M | -28.40M | -41.50M |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | -- | 0 | 0 | -- | -- | -800.00K |
| Ending cash balance | 266.50M | 278.90M | 901.90M | 646.40M | 672.90M | 460.70M |
Returns & efficiency
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| ROE %i | -32.19 | -- | -385.65 | -102.79 | -73.44 | -51.94 | -15.45 | -29.06 |
| ROA %i | -0.65 | -37.10 | -60.17 | -41.99 | -36.45 | -32.60 | -10.06 | -17.44 |
| ROIC %i | -56.00 | -- | -367.02 | -88.01 | -54.76 | -42.23 | -13.90 | -22.14 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- | -59.57 | -42.95 |
| EBIT margin %i | -3.12 | -227.28 | -406.24 | -429.11 | -371.72 | -174.76 | -21.76 | -25.39 |
| FCF / sales %i | 583.44 | -- | -- | -- | -- | -- | -- | -- |
| Current ratioi | 2.05 | 1.62 | 5.14 | 4.14 | 3.69 | 6.92 | 4.62 | 1.96 |
| Quick ratioi | 2.04 | 1.52 | 5.09 | 4.11 | 3.59 | 6.77 | 4.49 | 1.88 |
| Debt / assetsi | 1.01 | 2.11 | 0.47 | 10.98 | 21.38 | 17.78 | 20.99 | 23.86 |
| LT debt / equityi | 45.60 | -- | 0.32 | 15.94 | 37.75 | 26.01 | 33.23 | 8.70 |
| Interest coveragei | -18.71 | -583.62 | -1,576.55 | -428.12 | -40.29 | -22.87 | -6.32 | -12.21 |
| Revenue CAGR (3Y) %i | -- | -- | -- | 11.89 | 26.89 | 56.07 | 108.89 | 106.41 |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- | -- |
| Line item | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 | 2026-09 |
|---|---|---|---|---|---|---|
| ROE %i | -29.65 | -22.54 | -29.06 | -25.19 | -8.08 | -0.02 |
| ROA %i | -18.65 | -13.90 | -17.44 | -15.57 | -5.32 | -0.01 |
| ROIC %i | -23.89 | -17.90 | -22.14 | -18.86 | -6.57 | -0.37 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | -35.56 | -22.16 | -25.39 | -18.85 | -2.66 | 3.89 |
| FCF / sales %i | -- | -- | -- | -- | -- | -- |
| Current ratioi | 4.71 | 2.86 | 1.96 | 2.13 | 3.04 | 3.95 |
| Quick ratioi | 4.51 | 2.76 | 1.88 | 2.01 | 2.88 | 3.70 |
| Debt / assetsi | 22.95 | 23.95 | 23.86 | 24.38 | 15.89 | 9.96 |
| LT debt / equityi | 36.89 | 25.71 | 8.70 | 11.58 | 8.95 | 8.76 |
| Interest coveragei | -13.53 | -9.56 | -12.21 | -9.85 | -1.51 | 2.56 |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
Revenue breakdown most recent period
Business
Single segment100.00%
Quote time 2026-11-20 20:02:40 · For reference only, not investment advice and not tailored to your situation.
Legend Biotech discussion 0 comments